New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

The study found that N6LS (VH3810109 or VH109), given every four months in combination with already marketed monthly ...

ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 ...